Publicaciones en colaboración con investigadores/as de Pfizer (United States) (17)

2024

  1. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

  2. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing

    Clinical and Translational Oncology

  3. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

    New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55

2023

  1. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  2. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning

    Thrombosis Research, Vol. 228, pp. 181-188

2022

  1. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

    Oral Oncology, Vol. 115

2018

  1. Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

    Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174

2016

  1. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

    Gynecologic Oncology, Vol. 142, Núm. 1, pp. 62-69

2013

  1. Adaptación cultural al Español y validación psicométrica de la Escala de Beneficio del Tratamiento (Treatment Benefit Scale -TBS) en el tratamiento sintomático de la vejiga hiperactiva

    Medicina Clinica, Vol. 140, Núm. 1, pp. 6-13

  2. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool

    International Urogynecology Journal and Pelvic Floor Dysfunction, Vol. 24, Núm. 4, pp. 573-581

2012

  1. Quality of life in patients with overactive bladder: Validation and psychometric properties of the spanish overactive bladder questionnaire-short form

    Clinical Drug Investigation, Vol. 32, Núm. 8, pp. 523-532

2009

  1. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

    British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883

  2. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

2002

  1. Molecular profiling of angiogenesis markers

    American Journal of Pathology, Vol. 161, Núm. 1, pp. 35-41

2000

  1. New antiherpetic 1,3-phenylene derivatives, inhibitors of the interaction of the HSV-1 origin binding protein (OBP) with DNA

    Drug Design and Discovery, Vol. 16, Núm. 4, pp. 295-315